Equipment used in chemotherapy with a woman looking at her phone during her treatment in the background

PEACOCC: A trial of pembrolizumab in advanced clear-cell ovarian cancer

Trial at a glance

Closed trial

  • Cancer type: Epithelial – clear-cell
  • Treatment stage: Recurrence
  • Acronym: PEACOCC

PEACOCC: A phase II study of pembrolizumab in patients with advanced gynaecological clear-cell cancer

Who can take part

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.


You may be able to take part in this clinical trial if you:

  • clear-cell cancer of the gynaecological tract (ovary, fallopian tube, uterus, cervix, vagina or vulva)
  • already received at least one course of chemotherapy but their cancer is growing and needs further treatment

This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.

Recruitment for this trial is now closed. 

About the trial

The study will investigate whether women with clear-cell cancer may benefit from treatment with a new anti-cancer drug called pembrolizumab. All women in the study will receive the study drug, pembrolizumab, for up to two years or: 

  • until their study doctor thinks the study drug is no longer helping to control the cancer
  • if unacceptable side effects are seen
  • if the woman wishes to stop treatment

Some women may also be suitable for a possible retreatment period with pembrolizumab for up to one year if the cancer starts growing again.

The drug involved in this trial is:

  • Pembrolizumab a type of immunotherapy drug. It's designed to stimulate the body's immune system to 'see' and fight the cancer cells.

If you take part in this study, you'll attend clinic as an outpatient every three weeks for treatment. Pembrolizumab is given into a vein in the arm through a needle (intravenously) over 30 minutes once every three weeks (one treatment cycle).